Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.

Kloos RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, de Jonge R, van der Sluis IM.

Leuk Lymphoma. 2019 May 23:1-9. doi: 10.1080/10428194.2019.1613537. [Epub ahead of print]

PMID:
31120351
2.

Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis.

Klaassen ILM, Lauw MN, Fiocco M, van der Sluis IM, Pieters R, Middeldorp S, van de Wetering MD, de Groot-Kruseman HA, van Ommen CH.

Res Pract Thromb Haemost. 2019 Feb 27;3(2):234-241. doi: 10.1002/rth2.12182. eCollection 2019 Apr.

3.

Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.

Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, Warris A, Koch BCP, Brüggemann RJ.

Med Mycol. 2019 Nov 1;57(8):937-943. doi: 10.1093/mmy/myz006.

PMID:
30759261
4.

Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report.

Wolthers BO, Frandsen TL, Patel CJ, Abaji R, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Grosjean M, Krajinovic M, Larsen E, Liang DC, Möricke A, Rasmussen KK, Samarasinghe S, Silverman LB, van der Sluis IM, Stanulla M, Tulstrup M, Yadav R, Yang W, Zapotocka E, Gupta R, Schmiegelow K; Ponte di Legno toxicity working group.

Haematologica. 2019 Mar;104(3):556-563. doi: 10.3324/haematol.2018.199356. Epub 2018 Nov 22.

5.

A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.

Kloos RQH, van Litsenburg RRL, Wolf S, Wismans L, Kaspers GJL, Uyl-de Groot CA, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2019 Jan;66(1):e27458. doi: 10.1002/pbc.27458. Epub 2018 Sep 23.

PMID:
30246496
6.
7.

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.

van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM.

Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17.

8.

Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.

van der Sluis IM, de Groot-Kruseman H, Te Loo M, Tissing WJE, van den Bos C, Kaspers GJL, Bierings M, Kollen WJW, König T, Pichlmeier U, Kühnel HJ, Pieters R.

Pediatr Blood Cancer. 2018 Aug;65(8):e27083. doi: 10.1002/pbc.27083. Epub 2018 May 4.

PMID:
29727043
9.

Therapeutic Drug Monitoring of methotrexate in plasma using U-HPLC-MS/MS: necessary after administration of glucarpidase in methotrexate intoxications.

Mulder MB, Huisman R, Engels FK, van der Sluis IM, Koch BCP.

Ther Drug Monit. 2018 Apr 3. doi: 10.1097/FTD.0000000000000515. [Epub ahead of print]

PMID:
29621124
10.

A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.

Kloos RQH, Uyl-de Groot CA, van Litsenburg RRL, Kaspers GJL, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26651. Epub 2017 Aug 2.

PMID:
28766887
11.

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.

Wolthers BO, Frandsen TL, Baruchel A, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Grell K, Inaba H, Kovacs G, Liang DC, Mateos M, Mondelaers V, Möricke A, Ociepa T, Samarasinghe S, Silverman LB, van der Sluis IM, Stanulla M, Vrooman LM, Yano M, Zapotocka E, Schmiegelow K; Ponte di Legno Toxicity Working Group.

Lancet Oncol. 2017 Sep;18(9):1238-1248. doi: 10.1016/S1470-2045(17)30424-2. Epub 2017 Jul 20.

PMID:
28736188
12.

TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.

Klaassen ILM, Lauw MN, van de Wetering MD, Biemond BJ, Middeldorp S, Abbink FCH, Bierings M, Te Loo DMMW, Pieters R, van der Sluis IM, Tissing WJE, Michel Zwaan C, Heleen van Ommen C.

BMC Pediatr. 2017 May 10;17(1):122. doi: 10.1186/s12887-017-0877-x.

13.

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.

Sassen SD, Mathôt RA, Pieters R, Kloos RQ, de Haas V, Kaspers GJ, van den Bos C, Tissing WJ, Te Loo M, Bierings MB, Kollen WJ, Zwaan CM, van der Sluis IM.

Haematologica. 2017 Mar;102(3):552-561. doi: 10.3324/haematol.2016.149195. Epub 2016 Nov 10.

14.

Drug-drug interactions in pediatric oncology patients.

Balk TE, van der Sijs IH, van Gelder T, Janssen JJB, van der Sluis IM, van Leeuwen RWF, Engels FK.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26410. Epub 2017 Feb 16.

PMID:
28205376
15.

Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.

Kloos RQ, Pieters R, Escherich G, van der Sluis IM.

Pediatr Blood Cancer. 2016 Nov;63(11):1928-34. doi: 10.1002/pbc.26123. Epub 2016 Jul 4.

PMID:
27376478
16.

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.

van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, Sanchez de Toledo J, Rizzari C, Silverman LB, Whitlock JA.

Haematologica. 2016 Mar;101(3):279-85. doi: 10.3324/haematol.2015.137380.

17.

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.

Hijiya N, van der Sluis IM.

Leuk Lymphoma. 2016;57(4):748-57. doi: 10.3109/10428194.2015.1101098. Epub 2015 Nov 20. Review.

18.

Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.

den Hoed MA, Pluijm SM, te Winkel ML, de Groot-Kruseman HA, Fiocco M, Hoogerbrugge P, Leeuw JA, Bruin MC, van der Sluis IM, Bresters D, Lequin MH, Roos JC, Veerman AJ, Pieters R, van den Heuvel-Eibrink MM.

Haematologica. 2015 Dec;100(12):1564-70. doi: 10.3324/haematol.2015.125583. Epub 2015 Sep 24.

19.

Ammonia Levels Should Not Be Used as a Surrogate Marker of Levels of Asparaginase Activity in Acute Lymphoblastic Leukemia Patients.

Tong WH, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2016 Mar;63(3):564-5. doi: 10.1002/pbc.25767. Epub 2015 Sep 23. No abstract available.

PMID:
26397054
20.

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.

Tong WH, Pieters R, de Groot-Kruseman HA, Hop WC, Boos J, Tissing WJ, van der Sluis IM.

Haematologica. 2014 Nov;99(11):1716-21. doi: 10.3324/haematol.2014.109413. Epub 2014 Aug 22.

21.

Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.

van den Berk LC, van der Veer A, Willemse ME, Theeuwes MJ, Luijendijk MW, Tong WH, van der Sluis IM, Pieters R, den Boer ML.

Br J Haematol. 2014 Jul;166(2):240-9. doi: 10.1111/bjh.12883. Epub 2014 Apr 4.

PMID:
24697337
22.

Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase.

Tong WH, Pieters R, Tissing WJ, van der Sluis IM.

Haematologica. 2014 Jul;99(7):e102-4. doi: 10.3324/haematol.2013.099663. Epub 2014 Mar 28. No abstract available.

23.

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB, van den Bos C, Kollen WJ, Hop WC, Lanvers-Kaminsky C, Relling MV, Tissing WJ, van der Sluis IM.

Blood. 2014 Mar 27;123(13):2026-33. doi: 10.1182/blood-2013-10-534347. Epub 2014 Jan 21.

24.

Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol.

te Winkel ML, Pieters R, Hop WC, Roos JC, Bökkerink JP, Leeuw JA, Bruin MC, Kollen WJ, Veerman AJ, de Groot-Kruseman HA, van der Sluis IM, van den Heuvel-Eibrink MM.

Bone. 2014 Feb;59:223-8. doi: 10.1016/j.bone.2013.11.017. Epub 2013 Nov 25.

PMID:
24287213
25.

Asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.

Tong WH, Pieters R, Hop WC, van der Sluis IM.

Pediatr Blood Cancer. 2013 Nov;60(11):1914. doi: 10.1002/pbc.24661. Epub 2013 Jun 29. No abstract available.

PMID:
23813969
26.

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.

Tong WH, van der Sluis IM, Alleman CJ, van Litsenburg RR, Kaspers GJ, Pieters R, Uyl-de Groot CA.

Haematologica. 2013 May;98(5):753-9. doi: 10.3324/haematol.2012.073510. Epub 2013 Feb 12.

27.

No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.

Tong WH, Pieters R, Hop WC, Lanvers-Kaminsky C, Boos J, van der Sluis IM.

Pediatr Blood Cancer. 2013 Feb;60(2):258-61. doi: 10.1002/pbc.24292. Epub 2012 Sep 7.

PMID:
22961784
28.

Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.

Tong WH, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2012 Feb;58(2):317-8. doi: 10.1002/pbc.23266. Epub 2011 Aug 29. No abstract available.

PMID:
22162400
29.

Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.

te Winkel ML, Pieters R, Hop WC, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, Bökkerink JP, Leeuw JA, Bruin MC, Egeler RM, Veerman AJ, van den Heuvel-Eibrink MM.

J Clin Oncol. 2011 Nov 1;29(31):4143-50. doi: 10.1200/JCO.2011.37.3217. Epub 2011 Sep 26.

PMID:
21947829
30.

Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study.

te Winkel ML, de Muinck Keizer-Schrama SM, de Jonge R, van Beek RD, van der Sluis IM, Hop WC, Pieters R, van den Heuvel-Eibrink MM.

Bone. 2011 Mar 1;48(3):571-7. doi: 10.1016/j.bone.2010.10.163. Epub 2010 Oct 16.

PMID:
20955826
31.

Letter to the editor in response to "Prospective bone ultrasound patterns during childhood acute lymphoblastic leukemia" by Mussa et al.

te Winkel ML, van der Sluis IM, Lequin MH, Pieters R, van den Heuvel-Eibrink MM.

Bone. 2010 Oct;47(4):835-6; author reply 837-8. doi: 10.1016/j.bone.2010.07.004. Epub 2010 Jul 17. No abstract available.

PMID:
20624504
32.

Peak bone mineral density, lean body mass and fractures.

Boot AM, de Ridder MA, van der Sluis IM, van Slobbe I, Krenning EP, Keizer-Schrama SM.

Bone. 2010 Feb;46(2):336-41. doi: 10.1016/j.bone.2009.10.003. Epub 2009 Oct 13.

PMID:
19833245
33.

Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency.

Boot AM, van der Sluis IM, Krenning EP, de Muinck Keizer-Schrama SM.

Horm Res. 2009;71(6):364-71. doi: 10.1159/000223422. Epub 2009 Jun 9.

PMID:
19506395
34.

Fatal Aspergillus rhinosinusitis during induction chemotherapy in a child with acute lymphoblastic leukemia.

Vlaardingerbroek H, van der Flier M, Borgstein JA, Lequin MH, van der Sluis IM.

J Pediatr Hematol Oncol. 2009 May;31(5):367-9. doi: 10.1097/MPH.0b013e3181983c71.

PMID:
19415022
35.

Osteoporosis in children with cancer.

van der Sluis IM, van den Heuvel-Eibrink MM.

Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):474-8; discussion 486. Review.

PMID:
18064660
36.

Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up.

van der Sluis IM, Boot AM, Vernooij M, Meradji M, Kroon AA.

Eur J Pediatr. 2006 Sep;165(9):590-3. Epub 2006 Apr 29.

PMID:
16649023
37.

Direct X-ray radiogrammetry versus dual-energy X-ray absorptiometry: assessment of bone density in children treated for acute lymphoblastic leukaemia and growth hormone deficiency.

van Rijn RR, Boot A, Wittenberg R, van der Sluis IM, van den Heuvel-Eibrink MM, Lequin MH, de MuinckKeizer-Schrama SM, Van Kuijk C.

Pediatr Radiol. 2006 Mar;36(3):227-32. Epub 2006 Jan 24.

PMID:
16432701
38.

No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia.

van Beek RD, de Muinck Keizer-Schrama SM, Hakvoort-Cammel FG, van der Sluis IM, Krenning EP, Pieters R, van den Heuvel-Eibrink MM.

Pediatr Blood Cancer. 2006 Jan;46(1):88-93.

PMID:
15926166
39.

Estrogen receptor alpha gene polymorphisms and bone mineral density in healthy children and young adults.

Boot AM, van der Sluis IM, de Muinck Keizer-Schrama SM, van Meurs JB, Krenning EP, Pols HA, Uitterlinden AG.

Calcif Tissue Int. 2004 Jun;74(6):495-500.

PMID:
15354856
40.

Bone mineral density in childhood acute lymphoblastic leukemia (ALL) during and after treatment.

van der Sluis IM, de Muinck Keizer-Schrama SM, van den Heuvel-Eibrink MM.

Pediatr Blood Cancer. 2004 Aug;43(2):182-3; discussion 184. No abstract available.

PMID:
15236291
41.

Vitamin D receptor gene polymorphism predicts height and bone size, rather than bone density in children and young adults.

van der Sluis IM, de Muinck Keizer-Schrama SM, Krenning EP, Pols HA, Uitterlinden AG.

Calcif Tissue Int. 2003 Oct;73(4):332-8. Epub 2003 Jul 24.

PMID:
12874698
42.

Body composition in long-term survivors of childhood acute lymphoblastic leukemia (ALL).

van der Sluis IM, van den Heuvel MM, de Muinck Keizer-Schrama SM.

Med Pediatr Oncol. 2003 Jun;40(6):407. No abstract available.

PMID:
12692817
43.

Bone densitometry in children: a critical appraisal.

van Rijn RR, van der Sluis IM, Link TM, Grampp S, Guglielmi G, Imhof H, Glüer C, Adams JE, van Kuijk C.

Eur Radiol. 2003 Apr;13(4):700-10. Epub 2002 Sep 11. Review.

PMID:
12664106
44.

A longitudinal study using tibial ultrasonometry as a bone assessment technique in children with acute lymphoblastic leukaemia.

Lequin MH, van der Sluis IM, van den Heuvel-Eibrink MM, Hop WJ, van Rijn RR, de Muinck Keizer-Schrama SF, van Kuijk C.

Pediatr Radiol. 2003 Mar;33(3):162-7. Epub 2003 Jan 8.

PMID:
12612813
45.

Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study.

van der Sluis IM, Boot AM, Hop WC, De Rijke YB, Krenning EP, de Muinck Keizer-Schrama SM.

Horm Res. 2002;58(5):207-14.

PMID:
12401939
46.

Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults.

van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM.

Arch Dis Child. 2002 Oct;87(4):341-7; discussion 341-7.

47.

Collagen Ialpha1 polymorphism is associated with bone characteristics in Caucasian children and young adults.

van der Sluis IM, de Muinck Keizer-Schrama SM, Pols HA, Lequin MH, Krenning EP, Uitterlinden AG.

Calcif Tissue Int. 2002 Nov;71(5):393-9. Epub 2002 Sep 18.

PMID:
12232678
48.

Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia.

van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, Krenning EP, de Muinck Keizer-Schrama SM.

J Pediatr. 2002 Aug;141(2):204-10.

PMID:
12183715
49.

A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.

van der Sluis IM, Hop WC, van Leeuwen JP, Pols HA, de Muinck Keizer-Schrama SM.

Horm Res. 2002;57(5-6):170-9.

PMID:
12053089
50.

Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.

van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM.

J Clin Endocrinol Metab. 2002 Feb;87(2):506-12.

PMID:
11836277

Supplemental Content

Loading ...
Support Center